{"id":"https://openalex.org/W1586054331","doi":"https://doi.org/10.3109/10837450.2015.1078354","title":"Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats","display_name":"Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats","publication_year":2015,"publication_date":"2015-08-31","ids":{"openalex":"https://openalex.org/W1586054331","doi":"https://doi.org/10.3109/10837450.2015.1078354","mag":"1586054331","pmid":"https://pubmed.ncbi.nlm.nih.gov/26334707"},"language":"en","primary_location":{"id":"doi:10.3109/10837450.2015.1078354","doi":"https://doi.org/10.3109/10837450.2015.1078354","is_oa":false,"landing_page_url":"https://doi.org/10.3109/10837450.2015.1078354","pdf_url":null,"source":{"id":"https://openalex.org/S80622011","display_name":"Pharmaceutical Development and Technology","issn_l":"1083-7450","issn":["1083-7450","1097-9867"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutical Development and Technology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110217265","display_name":"Maha Mohamed Amin","orcid":"https://orcid.org/0009-0007-1719-1797","observed_orcids":["https://orcid.org/0009-0007-1719-1797"]},"institutions":[{"id":"https://openalex.org/I145487455","display_name":"Cairo University","ror":"https://ror.org/03q21mh05","country_code":"EG","type":"education","lineage":["https://openalex.org/I145487455"]}],"countries":["EG"],"is_corresponding":true,"raw_author_name":"Maha M. Amin","raw_affiliation_strings":["Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy , Cairo University , Cairo , Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy , Cairo University , Cairo , Egypt","institution_ids":["https://openalex.org/I145487455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078968799","display_name":"Omaima Naim El-Gazayerly","orcid":"https://orcid.org/0000-0001-8475-0412","observed_orcids":["https://orcid.org/0000-0001-8475-0412"]},"institutions":[{"id":"https://openalex.org/I145487455","display_name":"Cairo University","ror":"https://ror.org/03q21mh05","country_code":"EG","type":"education","lineage":["https://openalex.org/I145487455"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Omaima N. El Gazayerly","raw_affiliation_strings":["Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy , Cairo University , Cairo , Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy , Cairo University , Cairo , Egypt","institution_ids":["https://openalex.org/I145487455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034904487","display_name":"Nabaweya A. Abd El-Gawad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165376","display_name":"October 6 University","ror":"https://ror.org/05y06tg49","country_code":"EG","type":"education","lineage":["https://openalex.org/I4210165376"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Nabaweya A. Abd El-Gawad","raw_affiliation_strings":["Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, October 6 University, Sixth of October City, Egypt, and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, October 6 University, Sixth of October City, Egypt, and","institution_ids":["https://openalex.org/I4210165376"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014712378","display_name":"Shady M. Abd El\u2010Halim","orcid":"https://orcid.org/0000-0002-2716-4676","observed_orcids":["https://orcid.org/0000-0002-2716-4676"]},"institutions":[{"id":"https://openalex.org/I4210165376","display_name":"October 6 University","ror":"https://ror.org/05y06tg49","country_code":"EG","type":"education","lineage":["https://openalex.org/I4210165376"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Shady M. Abd El-Halim","raw_affiliation_strings":["Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, October 6 University, Sixth of October City, Egypt, and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, October 6 University, Sixth of October City, Egypt, and","institution_ids":["https://openalex.org/I4210165376"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020222707","display_name":"Sally A. El Awdan","orcid":"https://orcid.org/0000-0002-2840-1776","observed_orcids":["https://orcid.org/0000-0002-2840-1776"]},"institutions":[{"id":"https://openalex.org/I4210131959","display_name":"National Research Centre","ror":"https://ror.org/02n85j827","country_code":"EG","type":"facility","lineage":["https://openalex.org/I4210131959"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Sally A. El-Awdan","raw_affiliation_strings":["Department of Pharmacology, National Research Center, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, National Research Center, Cairo, Egypt","institution_ids":["https://openalex.org/I4210131959"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5110217265"],"corresponding_institution_ids":["https://openalex.org/I145487455"],"apc_list":null,"apc_paid":null,"fwci":0.7897,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.63529259,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"21","issue":"8","first_page":"909","last_page":"920"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10411","display_name":"Proteins in Food Systems","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1106","display_name":"Food Science"},"field":{"id":"https://openalex.org/fields/11","display_name":"Agricultural and Biological Sciences"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":1.0},{"id":"https://openalex.org/keywords/self-nanoemulsifying-drug-delivery-system","display_name":"self-nanoemulsifying drug delivery system","score":0.9160000085830688},{"id":"https://openalex.org/keywords/dissolution-enhancement","display_name":"dissolution enhancement","score":0.4869999885559082},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.9309999942779541},{"id":"https://openalex.org/keywords/ternary-phase-diagram","display_name":"ternary phase diagram","score":0.6990000009536743},{"id":"https://openalex.org/keywords/droplet-size","display_name":"droplet size","score":0.7279999852180481},{"id":"https://openalex.org/keywords/oxidative-stress","display_name":"oxidative stress","score":0.8870000243186951},{"id":"https://openalex.org/keywords/antioxidant-activity","display_name":"antioxidant activity","score":0.9160000085830688},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.8180000185966492},{"id":"https://openalex.org/keywords/low-water-solubility","display_name":"low water solubility","score":0.7710000276565552},{"id":"https://openalex.org/keywords/lipid-based-drug-delivery-systems","display_name":"lipid-based drug delivery","score":0.4230000078678131}],"concepts":[{"id":"https://openalex.org/C2777387769","wikidata":"https://www.wikidata.org/wiki/Q155472","display_name":"Valsartan","level":3,"score":0.8519662618637085},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.7797174453735352},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6289479732513428},{"id":"https://openalex.org/C58226133","wikidata":"https://www.wikidata.org/wiki/Q1324199","display_name":"Pulmonary surfactant","level":2,"score":0.614501953125},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5031864047050476},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.4811040759086609},{"id":"https://openalex.org/C2776525901","wikidata":"https://www.wikidata.org/wiki/Q411325","display_name":"Atenolol","level":3,"score":0.4295167624950409},{"id":"https://openalex.org/C155574463","wikidata":"https://www.wikidata.org/wiki/Q170731","display_name":"Solubility","level":2,"score":0.42619168758392334},{"id":"https://openalex.org/C2779820397","wikidata":"https://www.wikidata.org/wiki/Q1392806","display_name":"Drug delivery","level":2,"score":0.42165321111679077},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.17318862676620483},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1100209653377533},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10436812043190002},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068756","descriptor_name":"Valsartan","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000068756","descriptor_name":"Valsartan","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000068756","descriptor_name":"Valsartan","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000975","descriptor_name":"Antioxidants","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000975","descriptor_name":"Antioxidants","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000975","descriptor_name":"Antioxidants","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D004655","descriptor_name":"Emulsions","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004655","descriptor_name":"Emulsions","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004655","descriptor_name":"Emulsions","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004837","descriptor_name":"Epinephrine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D005079","descriptor_name":"Excipients","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010316","descriptor_name":"Particle Size","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012995","descriptor_name":"Solubility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013501","descriptor_name":"Surface-Active Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053758","descriptor_name":"Nanoparticles","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D053758","descriptor_name":"Nanoparticles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3109/10837450.2015.1078354","doi":"https://doi.org/10.3109/10837450.2015.1078354","is_oa":false,"landing_page_url":"https://doi.org/10.3109/10837450.2015.1078354","pdf_url":null,"source":{"id":"https://openalex.org/S80622011","display_name":"Pharmaceutical Development and Technology","issn_l":"1083-7450","issn":["1083-7450","1097-9867"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutical Development and Technology","raw_type":"journal-article"},{"id":"pmid:26334707","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26334707","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutical development and technology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W1874727364","https://openalex.org/W1945458326","https://openalex.org/W1968776115","https://openalex.org/W1975404927","https://openalex.org/W1975405254","https://openalex.org/W1978129161","https://openalex.org/W1980960820","https://openalex.org/W1984897061","https://openalex.org/W1988249648","https://openalex.org/W1989392090","https://openalex.org/W1989602366","https://openalex.org/W2000820845","https://openalex.org/W2002388452","https://openalex.org/W2003952694","https://openalex.org/W2012819347","https://openalex.org/W2020487511","https://openalex.org/W2021036563","https://openalex.org/W2022571369","https://openalex.org/W2036513055","https://openalex.org/W2038365601","https://openalex.org/W2053054955","https://openalex.org/W2062523168","https://openalex.org/W2067954654","https://openalex.org/W2077890234","https://openalex.org/W2084604144","https://openalex.org/W2089926889","https://openalex.org/W2090241136","https://openalex.org/W2097361496","https://openalex.org/W2107343318","https://openalex.org/W2108542559","https://openalex.org/W2109323137","https://openalex.org/W2114501722","https://openalex.org/W2119023371","https://openalex.org/W2124015480","https://openalex.org/W2154862932","https://openalex.org/W2166547808","https://openalex.org/W2182216305","https://openalex.org/W2183216894","https://openalex.org/W2186869362","https://openalex.org/W2524072391","https://openalex.org/W2593230838","https://openalex.org/W2883241738","https://openalex.org/W4242516997","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2021646147","https://openalex.org/W2548955100","https://openalex.org/W7217075383","https://openalex.org/W1794192845","https://openalex.org/W7093349906","https://openalex.org/W2549371484","https://openalex.org/W4406751512","https://openalex.org/W4313454879","https://openalex.org/W2003952694","https://openalex.org/W7090258457"],"abstract_inverted_index":{"Valsartan":[0,43,103,139],"is":[1],"a":[2,153,171,192],"specific":[3],"angiotensin":[4],"II":[5],"antagonist":[6],"used":[7],"for":[8],"the":[9,36,40,45,61,111,197,201],"treatment":[10],"of":[11,30,42,47,64,90,110,131,138,203],"hypertension.":[12],"It":[13],"suffers":[14],"from":[15],"low":[16],"aqueous":[17],"solubility":[18],"and":[19,38,71,79,85,94,100,167,199],"high":[20],"variability":[21],"in":[22,101,115,119,159,177,180],"its":[23],"absorption":[24],"after":[25,141],"oral":[26],"administration.":[27],"The":[28,88,107],"aim":[29],"this":[31],"study":[32],"was":[33,124],"to":[34,59,145,195],"improve":[35,196],"dissolution":[37,104,198],"thereby":[39,200],"bioavailability":[41,202],"through":[44],"development":[46],"self":[48,183],"nano-emulsifying":[49,184],"drug":[50,185],"delivery":[51,186],"systems.":[52],"Four":[53],"ternary":[54],"phase":[55],"diagrams":[56],"were":[57,105],"constructed":[58],"identify":[60],"self-emulsification":[62],"region":[63],"Capmul\u00ae":[65],"MCM,":[66],"Labrafil\u00ae":[67],"M1944,":[68],"Capryol\u2122":[69],"90":[70],"Labrafac\u00ae":[72],"PG":[73],"together":[74],"with":[75,134],"Cremophore\u00ae":[76],"RH":[77],"40":[78],"Transcutol\u2122":[80],"HP":[81],"as":[82,191],"oil,":[83],"surfactant":[84,95],"co-surfactant,":[86],"respectively.":[87],"effect":[89,109],"oil":[91,93],"type,":[92],"concentration":[96],"on":[97],"droplet":[98],"size":[99,130],"vitro":[102],"studied.":[106],"protective":[108],"optimum":[112],"formula":[113],"F5":[114,127],"adrenaline-induced":[116],"oxidative":[117],"stress":[118],"rats":[120],"during":[121],"myocardial":[122,165],"infarction":[123],"determined.":[125],"Formula":[126],"exhibited":[128],"globule":[129],"(13.95":[132],"nm)":[133],"76.07%":[135],"\u00b1":[136],"1.10":[137],"dissolved":[140],"five":[142],"minutes":[143],"compared":[144],"Disartan":[146],"80":[147],"mg":[148],"capsules":[149],"(13.43%).":[150],"Results":[151],"revealed":[152],"significant":[154,172],"reduction":[155],"(p":[156,174],"<":[157,175],"0.05)":[158,176],"serum":[160,178],"aspartate":[161],"transaminase,":[162],"creatine":[163],"kinase":[164],"band":[166],"malondialdehyde":[168],"levels,":[169],"while":[170],"increase":[173],"glutathione":[179],"F5.":[181],"Therefore,":[182],"systems":[187],"could":[188],"be":[189],"considered":[190],"promising":[193],"approach":[194],"Valsartan.":[204]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}